CYTEA BIO

CYTEA BIO is a Swiss/French biotechnology company focused on developing therapeutic products using a proprietary Pin™ platform. This platform combines genetically unmodified effector cells with engineered targeting ligands, creating modular constructs for oncology and immunology applications. The lead product, CYT-102, targets solid glioblastoma multiforme (GBM) and other EGFR-positive solid tumors. CYTEA BIO’s innovative approach aims to address residual tumor challenges post-surgery, potentially improving outcomes for GBM patients, a condition with limited effective treatments and a poor prognosis.

The company, currently in the preclinical stage, has completed pre-IND consultations with both the FDA and EMA, with no significant regulatory obstacles identified. CYTEA BIO plans to advance to clinical studies after securing additional funding. It operates as part of MedXCell's portfolio, which supports early-stage biotech ventures and helps transition them into independent entities ready for clinical development.